Iowa Senate Bill SSB1169

Iowa 2025-2026 Regular Session

• Introduced: 2/20/25
• Refer: 2/20/25

Caption

A bill for an act relating to nonopioid drugs on the medical assistance preferred drug list, and health carriers' development of a pain management access plan.

Impact

The legislation impacts state laws pertaining to the preferred drug lists administered by Medicaid, requiring them to favor nonopioid medications equally alongside opioids. This is an important change in state healthcare policy aimed at promoting alternative pain management therapies that avoid the addictive potential of opioid medications. The regulations also establish standards for utilization controls applicable to these medications, which could lead to broader access to safer pain management options for Medicaid beneficiaries.

Summary

Senate Study Bill 1169 addresses the regulations surrounding the inclusion of nonopioid drugs in the medical assistance preferred drug list, particularly for pain management. The bill introduces measures to ensure that nonopioid drugs, once approved by the FDA for pain management, are not disadvantaged compared to opioids and narcotics regarding Medicaid coverage. Specifically, it prohibits the designation of nonopioid drugs as nonpreferred if their opioid counterparts are preferred, indicating a drive towards equitable treatment of pain management options within state guidelines.

Contention

Notable points of contention likely revolve around the potential resistance from pharmaceutical companies that produce opioid medications, who may see this bill as undermining their product's preferred status. Additionally, there may be concerns regarding implementation and monitoring of compliance by health carriers to ensure they do not favor opioids over nonopioids. This bill represents a significant shift in addressing the opioid crisis while seeking to give patients and healthcare providers alternative options for managing pain without resorting to narcotics.